Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MedImmune's Restructured Oncology Unit Displays Its Fruits At AACR

Executive Summary

MedImmune's R&D reorganization into therapeutic business units takes the start-to-finish, integrated approach that has become trendy with big pharmas trying to capture the innovative spirit of small biotech – and the oncology pipeline will be a key test of how that restructuring delivers.

You may also be interested in...



MedImmune Pipeline Primed To Produce

MedImmune, the biologics arm of performance-challenged AstraZeneca, is poised to lead the parent company into more prosperous times, with positive signals coming from Phase II trials in oncology and asthma and a stake in cancer immunotherapies.

MedImmune's Biologic Solution To Blocking IGF In Solid Tumors Heads Into Phase II Studies

MIDI-573, which blocks insulin-like growth factor I and II while sparing receptors for normal glucose processing, heads into multiple Phase II studies this year accompanied by an assay to prospectively identify patient populations for further study, MedImmune head of oncology McMahon said in an April 4 interview at AACR.

A Look Back At 2010: In Search Of New Biopharma Models

2010 was a year of transition, filled with the exploration of new industry models. Health care reform hinted at short-term pain and long-term gain while investment, R&D and commercial challenges combined with a heightened sense of industry desperation to bring out biopharma's creative side. But as with any experiment, there is ample risk of failure.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS053308

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel